One analyst described Cogent’s data as a “home run scenario” for bezuclastinib, which the company is positioning as a a ...

Blueprint Medicines (BPMC) shares are soaring after Sanofi (SNY) agreed to acquire the company for up to $9.5 billion. Boeing (BA) shares were upgrade to Buy from Neutral at Bank of Bank of America.

Learn about June 2025’s top biotech deals, featuring major collaborations in small molecules, protein therapeutics, and ...

AbbVie ABBV has been actively ramping up its deal-making efforts lately, thereby strengthening its pipeline. While immunology ...

A phase 3 trial of Cogent Biosciences’ bezuclastinib has hit its primary endpoint, teeing the biotech up to seek FDA approval ...

Cogent Biosciences said its experimental drug reduced the symptoms of a chronic immune disorder called indolent systemic ...

Sanofi has entered into an agreement to acquire Blueprint Medicines for $129 per share, or about $9.1 billion. Additional contingent value rights bring the total potential deal value to $9.5 billion.

Learn about the executive team and board of directors at Blueprint Medicines Corp (BPMC:XNAS) and review their bios and compensation over the latest fiscal years.

France's Sanofi is the latest European pharma group to promise a big capital investment programme on manufacturing and R&D in the US, saying it intends to spend "at least $20 billion" there by the ...

Apple’s efforts to expand its manufacturing footprint in India have hit a roadblock. Foxconn, the tech giant’s key assembly partner, has quietly recalled a la ...

Sanofi has added another dimension to the use of artificial intelligence (AI) to seek out new drugs, partnering with BioMap on a project to find biologic therapies in a deal that could be worth up ...

The leading Chronic Urticaria Companies such as Synermore Biologics, Incyte Corporation, Jasper Therapeutics, Novartis, ...